To the editor: In a recent paper by Hauser et al. in this journal, a prevalence of 10.8% of transmitted drugresistant viruses was reported among newly diagnosed HIV cases in Germany in 2013 and 2014.
The authors conclude that genotypic resistance testing remains important for treatment as well as HIV prevention. We comment on the use of pre-exposure prophylaxis (PrEP) in relation to drug resistance in HIV infections and the need for European surveillance of drug resistance.

Additional Metadata
Persistent URL dx.doi.org/10.2807/1560-7917.ES.2017.22.11.30483, hdl.handle.net/1765/98843
Journal Eurosurveillance
Citation
Van Tienen, C, van de Vijver, D.A.M.C, Noori, T, Sonnerborg, A, & Boucher, C.A.B. (2017). Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance. Eurosurveillance, 22(11). doi:10.2807/1560-7917.ES.2017.22.11.30483